208 related articles for article (PubMed ID: 32980613)
1. Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients.
Alborelli I; Bratic Hench I; Chijioke O; Prince SS; Bubendorf L; Leuenberger LP; Tolnay M; Leonards K; Quagliata L; Jermann P; Matter MS
Lung Cancer; 2020 Nov; 149():84-89. PubMed ID: 32980613
[TBL] [Abstract][Full Text] [Related]
2. A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay.
Chaudhary R; Quagliata L; Martin JP; Alborelli I; Cyanam D; Mittal V; Tom W; Au-Young J; Sadis S; Hyland F
Transl Lung Cancer Res; 2018 Dec; 7(6):616-630. PubMed ID: 30505706
[TBL] [Abstract][Full Text] [Related]
3. Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay.
Quy PN; Kanai M; Fukuyama K; Kou T; Kondo T; Yamamoto Y; Matsubara J; Hiroshima A; Mochizuki H; Sakuma T; Kamada M; Nakatsui M; Eso Y; Seno H; Masui T; Takaori K; Minamiguchi S; Matsumoto S; Muto M
Oncologist; 2019 Dec; 24(12):e1401-e1408. PubMed ID: 31186376
[TBL] [Abstract][Full Text] [Related]
4. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
5. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A
Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutational burden on cytological samples: A pilot study.
Pepe F; Pisapia P; Gristina V; Rocco D; Micheli M; Micheli P; Iaccarino A; Tufano R; Gragnano G; Russo G; De Luca C; Sgariglia R; Nacchio M; Girolami I; Eccher A; Russo A; Troncone G; Malapelle U
Cancer Cytopathol; 2021 Jun; 129(6):460-467. PubMed ID: 33378102
[TBL] [Abstract][Full Text] [Related]
7. Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma.
Wong CN; Fessas P; Dominy K; Mauri FA; Kaneko T; Parcq PD; Khorashad J; Toniutto P; Goldin RD; Avellini C; Pinato DJ
Liver Int; 2021 Jan; 41(1):192-203. PubMed ID: 33098208
[TBL] [Abstract][Full Text] [Related]
8. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium.
Fenizia F; Alborelli I; Costa JL; Vollbrecht C; Bellosillo B; Dinjens W; Endris V; Heydt C; Leonards K; Merkelback-Bruse S; Pfarr N; van Marion R; Allen C; Chaudhary R; Gottimukkala R; Hyland F; Wong-Ho E; Jermann P; Machado JC; Hummel M; Stenzinger A; Normanno N
J Mol Diagn; 2021 Jul; 23(7):882-893. PubMed ID: 33964449
[TBL] [Abstract][Full Text] [Related]
9. Deep targeted sequencing of cytological tumor cells using whole genome amplification.
Amemiya K; Hirotsu Y; Mochizuki H; Higuchi R; Nakagomi T; Goto T; Oyama T; Kondo T; Omata M
Cancer Cytopathol; 2023 Jan; 131(1):58-68. PubMed ID: 36219530
[TBL] [Abstract][Full Text] [Related]
10. Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.
Velizheva NP; Rechsteiner MP; Wong CE; Zhong Q; Rössle M; Bode B; Moch H; Soltermann A; Wild PJ; Tischler V
Cancer Cytopathol; 2017 Jan; 125(1):30-40. PubMed ID: 27636102
[TBL] [Abstract][Full Text] [Related]
11. Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.
Kazdal D; Endris V; Allgäuer M; Kriegsmann M; Leichsenring J; Volckmar AL; Harms A; Kirchner M; Kriegsmann K; Neumann O; Brandt R; Talla SB; Rempel E; Ploeger C; von Winterfeld M; Christopoulos P; Merino DM; Stewart M; Allen J; Bischoff H; Meister M; Muley T; Herth F; Penzel R; Warth A; Winter H; Fröhling S; Peters S; Swanton C; Thomas M; Schirmacher P; Budczies J; Stenzinger A
J Thorac Oncol; 2019 Nov; 14(11):1935-1947. PubMed ID: 31349062
[TBL] [Abstract][Full Text] [Related]
12. Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.
Zhang W; Wang R; Fang H; Ma X; Li D; Liu T; Chen Z; Wang K; Hao S; Yu Z; Chang Z; Na C; Wang Y; Bai J; Zhang Y; Chen F; Li M; Chen C; Wei L; Li J; Chang X; Qu S; Yang L; Huang J
Clin Transl Med; 2021 May; 11(5):e415. PubMed ID: 34047470
[TBL] [Abstract][Full Text] [Related]
13. Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy.
Pinato DJ; Urus H; Newsom-Davis T; Du Parcq P; Belessiotis K; Mapara L; Gupta N; Power D; Weir J; Wong CN; Ratnakumaran RP; Dominy K; Khorashad J; Bower M
J Immunother; 2020; 43(2):53-56. PubMed ID: 31567705
[TBL] [Abstract][Full Text] [Related]
14. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M
Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282
[TBL] [Abstract][Full Text] [Related]
15. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions.
Stenzinger A; Allen JD; Maas J; Stewart MD; Merino DM; Wempe MM; Dietel M
Genes Chromosomes Cancer; 2019 Aug; 58(8):578-588. PubMed ID: 30664300
[TBL] [Abstract][Full Text] [Related]
16. Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.
Dupain C; Gutman T; Girard E; Kamoun C; Marret G; Castel-Ajgal Z; Sablin MP; Neuzillet C; Borcoman E; Hescot S; Callens C; Trabelsi-Grati O; Melaabi S; Vibert R; Antonio S; Franck C; Galut M; Guillou I; Halladjian M; Allory Y; Cyrta J; Romejon J; Frouin E; Stoppa-Lyonnet D; Wong J; Le Tourneau C; Bièche I; Servant N; Kamal M; Masliah-Planchon J
BMC Biol; 2024 Feb; 22(1):43. PubMed ID: 38378561
[TBL] [Abstract][Full Text] [Related]
17. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
18. External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme.
Esposito Abate R; Cheetham MH; Fairley JA; Pasquale R; Sacco A; Nicola W; Deans ZC; Patton SJ; Normanno N
Virchows Arch; 2023 Feb; 482(2):347-355. PubMed ID: 36355212
[TBL] [Abstract][Full Text] [Related]
19. Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.
Wu HX; Wang ZX; Zhao Q; Wang F; Xu RH
J Immunother Cancer; 2019 Aug; 7(1):206. PubMed ID: 31387639
[TBL] [Abstract][Full Text] [Related]
20. Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort.
Bevins N; Sun S; Gaieb Z; Thorson JA; Murray SS
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
